Co-detection of respiratory pathogens among ILI patients: characterization of samples collected during the 2018/19 and 2019/20 pre-pandemic seasons

Autor: Allegra Ferrari, Irene Schiavetti, Matilde Ogliastro, Carola Minet, Raffaella Sibilio, Irene Giberti, Elisabetta Costa, Elvira Massaro, Piero Luigi Lai, Stefano Mosca, Bianca Bruzzone, Andrea Orsi, Donatella Panatto, Giancarlo Icardi

Publikováno v: BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)

Abstract Influenza-like illness (ILI) patients co-detected with respiratory pathogens exhibit poorer health outcomes than those with single infections. To address the paucity of knowledge concerning the incidence of concurrent respiratory pathogens,

Externí odkaz: https://doaj.org/article/ad4c8d997b1e42309d2d1335ae16f57e

Health Technology Assessment of Vaccines in Italy: History and Review of Applications

Autor: Sara Boccalini, Rosalia Ragusa, Donatella Panatto, Giovanna Elisa Calabrò, Paolo Angelo Cortesi, Gabriele Giorgianni, Carlo Favaretti, Paolo Bonanni, Walter Ricciardi, Chiara de Waure

Publikováno v: Vaccines, Vol 12, Iss 10, p 1090 (2024)

Background/Objectives. Many vaccines have been developed in recent decades, and many more will be available in the future. When new safe and effective vaccines are available, decision-makers must extensively assess them before including them in the n

Externí odkaz: https://doaj.org/article/6e01a2e53e394706b74d6709b8bb3277

Epidemiology and molecular characteristics of respiratory syncytial virus (RSV) among italian community-dwelling adults, 2021/22 season

Autor: Donatella Panatto, Alexander Domnich, Piero Luigi Lai, Matilde Ogliastro, Bianca Bruzzone, Cristina Galli, Federica Stefanelli, Elena Pariani, Andrea Orsi, Giancarlo Icardi

Publikováno v: BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-10 (2023)

Abstract Background Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections worldwide. While historically RSV research has been focused on children, data on RSV infection in adults are limited. The goal of this study was

Externí odkaz: https://doaj.org/article/2e48d36b45bb4faab3bff55e78cb8552

Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine

Autor: Alexander Domnich, Daniela Amicizia, Piero Luigi Lai, Matilde Ogliastro, Maria Piedrahita-Tovar, Andrea Orsi, Giancarlo Icardi, Donatella Panatto

Publikováno v: Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)

The objective of this paper is to summarize annual enhanced safety surveillance activity across three seasons (2019/20–2021/22) for cell culture-based quadrivalent influenza vaccine (QIVc; Flucelvax® Tetra) in all age groups. This activity was con

Externí odkaz: https://doaj.org/article/69bfbc69cfb342008f81472dc6b10c03

Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform

Autor: Anke L. Stuurman, Antonio Carmona, Jorne Biccler, Alexandre Descamps, Miriam Levi, Ulrike Baum, Ainara Mira-Iglesias, Stefania Bellino, Uy Hoang, Simon de Lusignan, Roberto Bonaiuti, Bruno Lina, Caterina Rizzo, Hanna Nohynek, Javier Díez-Domingo, DRIVE Study Contributors, Anca Cristina Drăgănescu, Oana Săndulescu, Daniela Piţigoi, Victor Daniel Miron, Anca Streinu-Cercel, Anuţa Bilaşco, Adrian Streinu-Cercel, Dragoş Florea, Ovidiu Vlaicu, Simona Paraschiv, Leontina Bănică, Dan Oţelea, Monika Redlberger-Fritz, Eva Geringer, Amparo López-Bernus, Ana Haro Perez, Nieves Gutierrez Zufiaurre, Cristina Carbonell Muñoz, Miguel Marcos Martin, Muñoz Juan Luis Bellido, Isabel Gil Rodríguez, Antonio Muro Alvarez, Moncef Belhassen Garcia, Giancarlo Icardi, Stefano Mosca, Donatella Panatto, Emanuele Montomoli, Silvana Castaldi, Andrea Orsi, Alexander Domnich, Maria Chironna, Daniela Loconsole, Ilaria Manini, Christian Napoli, Alessandra Torsello, Elena Pariani, and Piero Luigi Lai, Susana Otero-Romero, Andrés Antón Pagarolas, Cristina Andrés, Ingrid Carbonés, Oleguer Pares, Mar Fornaguera, Anna Oller, Xavier Salgado, Patricia Tejerina, Cristina Martinez, Alejandro Orrico-Sánchez, F. Xavier López-Labrador, Beatriz Mengual-Chuliá, Judit Sánchez Soler, María Jinglei Casanova Palomino, Juan Mollar-Maseres, Miguel Tortajada-Girbés, Noelia Rodríguez-Blanco, Mario Carballido-Fernández, Raquel Andreu Ivorra, Àngels Sierra Fortuny, Beatriz Segura Segura, Cristina Mingot Ureta, Sagrario Corrales Díaz-Flores, Ángela Sánchez Pla, María Dolores Tirado Balaguer, Juan Alberola, José Miguel Nogueira, Juan J Camarena, Francisco Arjona-Zaragozí, Maruan Shalabi Benavent, José Luis López-Hontangas, María Dolores Gómez, Alejandro Martín-Quirós, Carlos Cañada Illana, Emilio Cendejas, Irma Casas García, Guillermo Mena Pinilla, María Esteve Pardo, Lola Álamo Junquera, Cristina Casañ, Sandra Fernandez Morodo, Agueda Hernández, Pere-Joan Cardona, Marta Segura, Andreu C. Pelegrin, Sara González-Gómez, Verónica Saludes, Elisa Martró, Valtýr Stefánsson Thors, Kristín L. Björnsdóttir, Liem Luong, Zineb Lesieur, Yacine Saidi, Rebecca Bauer, Christine Pereira, Philippe Vanhems, Fabrice Lainé, Florence Galtier, Xavier Duval, Christine Durier, Paolo Bonanni, Alfredo Vannacci, Claudia Ravaldi

Publikováno v: Frontiers in Public Health, Vol 11 (2023)

IntroductionDevelopment of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public–private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public

Externí odkaz: https://doaj.org/article/75fb3f72a3704f36bf12c2869d3a6c12